Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...

InvestingPro analysis suggests the stock is currently trading near its Fair Value, with analysts setting price targets ranging from $125 to $166. Despite some modest price recovery in PE and PVC ...

Hims stock stood about 22% lower in recent trading. Novo Nordisk shares jumped as much as 4% in Denmark. Hims will stop offering mass compounding of semaglutide after the first quarter ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss treatments. Metsera shares are going for $30 at writing versus their IPO ...

The U.S. stock market was mostly up early afternoon Monday, with the equal-weight version of the S&P 500 staging a partial recovery from Friday’s slump. The Invesco S&P 500 Equal Weight ETF ...

Analyst upgrades can temporarily boost a stock's price; opportunity for short gains. Downgrades often cause immediate selling and lower stock prices; buying chance for others. Long-term investors ...

Eli Lil­ly has amassed a stock­pile of soon-to-be-launched drugs and re­lat­ed ma­te­ri­als, pri­mar­i­ly its oral GLP-1 can­di­date or­for­glipron, worth more than half a bil­lion ...

Will LNW Stock Benefit From This Acquisition? Headquartered in Greenville, NC, Grover Charitable Gaming has a strong presence in the fast-growing charitable gaming space. It operates around 10,000 ...